Alpha-Synuclein

Alpha-synuclein is a protein found primarily in the brain, which plays a role in regulating synaptic vesicle trafficking and neurotransmitter release. However, when alpha-synuclein misfolds and aggregates, it becomes a key player in several neurodegenerative diseases, most notably Parkinson's disease (PD) and dementia with Lewy bodies (DLB). 

Testing for alpha-synuclein levels can provide valuable insights into these conditions' presence, progression, and severity. 

What is Alpha-Synuclein?

Alpha-synuclein is a protein found in nerve cells, particularly at the presynaptic terminals, where it helps regulate neurotransmitter release for cell communication. 

In Parkinson's disease and other synucleinopathies, abnormal accumulation and misfolding of alpha-synuclein lead to the formation of toxic aggregates that disrupt cellular function and cause neurodegeneration. These misfolded proteins, called Lewy bodies, can impair synaptic function and energy production, often before visible neuron loss occurs. 

Genetic mutations in the SNCA gene can lead to familial Parkinson's disease and other nervous system diseases, and abnormal levels of alpha-synuclein in cerebrospinal fluid are being explored as potential biomarkers for early diagnosis and monitoring of these conditions.

How is Alpha-Synuclein Involved In Certain Neurodegenerative Disorders?

Neurodegenerative diseases involving alpha-synuclein pathologies, such as Parkinson's disease and related synucleinopathies, are driven by the accumulation of abnormal alpha-synuclein proteins that form toxic aggregates in neurons. 

These aggregates disrupt cellular processes, including mitochondrial function, calcium balance, and lysosomal activity, leading to progressive neuronal damage. 

In the early stages, alpha-synuclein aggregates trigger synaptic dysfunction and neuroinflammation, which precede visible neurodegeneration. This early dysfunction affects dopamine transmission and alters synaptic plasticity, particularly in dopaminergic neurons, contributing to motor and cognitive impairments. 

Testing Procedure and Interpretation

Testing for alpha-synuclein may involve testing for the protein itself or a genetic analysis to determine whether the patient has a mutation in the SNCA gene. 

Additionally, some companies now offer antibody testing to assess for an immune response against the alpha-synuclein protein as an alternative method of determining an individual’s risk of developing a neurodegenerative condition.

Testing Procedure

Testing for alpha-synuclein levels typically involves either cerebrospinal fluid (CSF) analysis or blood samples. CSF analysis remains the gold standard for detecting alpha-synuclein aggregates, although it is an invasive test that requires a lumbar puncture.

Blood tests are also available, and they require a simple blood draw. Blood tests are also used to determine whether there is an immune response against the alpha-synuclein antibody.

A skin biopsy test can also detect abnormal alpha-synuclein (P-SYN) in nerve fibers, offering a high degree of accuracy in identifying Parkinson's disease and related neurodegenerative disorders. This could potentially enable earlier and more reliable diagnoses.

Genetic testing may involve blood, saliva, or a cheek swab. 

Normal Reference Range

The reference range for alpha-synuclein levels can vary depending on the testing assay used and patient demographics. Always consult with the laboratory company used for their recommended reference range.

Generally speaking, elevated levels may be associated with neurodegenerative disease.

Clinical Significance of High Levels

Elevated alpha-synuclein levels are commonly seen in patients with Parkinson’s disease and related diseases such as dementia with Lewy bodies.

In these cases, high levels can indicate active disease, neurodegenerative progression, or poor response to treatment. The presence of high alpha-synuclein levels in CSF is often used as a diagnostic marker for Parkinson's disease and is correlated with disease severity.

Clinical Significance of Low Levels

Low alpha-synuclein levels may indicate an absence of disease or be found in the early stages of disease before significant aggregation occurs. 

Low levels may also suggest a non-specific result, influenced by factors like sample degradation or technical issues during testing.

Limitations of Testing

While alpha-synuclein testing has high diagnostic utility, it is not without limitations. False positives and false negatives can occur, mainly due to the influence of other conditions that may affect alpha-synuclein levels. 

Clinicians should interpret alpha-synuclein test results alongside clinical symptoms and other diagnostic findings. Additionally, alpha-synuclein testing is still developing, and further research is needed to improve its reliability and application in clinical practice.

Order Alpha-Synuclein Antibody Testing

Click here to discover and order antibody testing for the alpha-synuclein protein.